Flucelvax (Optaflu) for seasonal influenza

References

• Fauci AS. Seasonal and pandemic influenza preparedness: science and countermeasures. J Infect Dis 2006;194(Suppl 2):S73-6
   PubMedGoogle Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25(27):5086-96
   PubMed Web of Science ®Google Scholar
• Lai PL, Panatto D, Ansaldi F, et al. Burden of the 1999-2008 seasonal influenza epidemics in Italy: comparison withthe H1N1v (A/California/07/09) pandemic. Hum Vaccin 2011;7(Suppl):217-25
   PubMedGoogle Scholar
• World Health Organization (WHO). Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec 2012;87(47):461-76
   PubMedGoogle Scholar
• Mereckiene J, Cotter S, Nicoll A, et al. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Euro Surveill 2014;19(16):20780
   PubMedGoogle Scholar
• CDC’s Advisory Committee on Immunization Practices (ACIP) recommends universal annual influenza vaccination. Press release. Available from: www.cdc.gov/media/pressrel/2010/r100224.htm
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Guidance Priority risk groups for influenza vaccination. ECDC; Stockholm: 2008
   Google Scholar
• Council recommendation of 22 December 2009 on seasonal influenza vaccination. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF
   Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Influenza vaccination. Available from: www.ecdc.europa.eu/en/healthtopics/seasonal_influenza/vaccines/Pages/influenza_vaccination.aspx
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Influenza vaccines – United States, 2014-15 influenza season. Available from: www.cdc.gov/flu/pdf/protect/vaccine/influenza-vaccines-table-2014-15.pdf
   Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012;8(1):81-8
   PubMed Web of Science ®Google Scholar
• Gasparini R, Amicizia D, Lai PL, Panatto D. Live attenuated influenza vaccine – a review. J Prev Med Hyg 2011;52(3):95-101
   PubMedGoogle Scholar
• Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol 2009;333:43-82
   PubMedGoogle Scholar
• Sheridan C. Production technologies change flu vaccine landscape. Nat Biotechnol 2007;25(7):701
   PubMedGoogle Scholar
• World Health Organization (WHO). Global action plan for influenza vaccines: Global progress report: January 2006 – September 2013. WHO; Geneva: 2014
   Google Scholar
• Groth N, Montomoli E, Gentile C, et al. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009;27(5):786-91
   PubMed Web of Science ®Google Scholar
• Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev 2013;26(3):476-92
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Optaflu. Authorization details. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000758/human_med_000952.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Food and Drug Administration (FDA). Approval letter – Flucelvax. Available from: www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm328684.htm
   Google Scholar
• Noh JY, Kim WJ. Influenza vaccines: unmet needs and recent developments. Infect Chemother 2013;45(4):375-86
   PubMedGoogle Scholar
• Kresse H, Rovini H. Influenza vaccine market dynamics. Nat Rev Drug Discov 2009;8(11):841-2
   PubMedGoogle Scholar
• Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture–derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010;51(9):997-1004
   PubMed Web of Science ®Google Scholar
• Alexander DJ. An overview of the epidemiology of avian influenza. Vaccine 2007;25(30):5637-44
   PubMed Web of Science ®Google Scholar
• Montomoli E, Khadang B, Piccirella S, et al. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert Rev Vaccines 2012;11(5):587-94
   PubMed Web of Science ®Google Scholar
• Gregersen JP. A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine 2008;26(26):3297-304
   PubMed Web of Science ®Google Scholar
• Donis RO; Influenza Cell Culture Working Group; Influenza Cell Culture Working Group. Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing. Vaccine 2014;32(48):6583-90
   PubMedGoogle Scholar
• Ampofo WK, Bachtiar NS, Bakamutumaho B, et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses 2012;6(2):142-52
   PubMedGoogle Scholar
• Neuzil KM, Bright RA. Influenza vaccine manufacture: keeping up with change. J Infect Dis 2009;200(6):835-7
   PubMed Web of Science ®Google Scholar
• Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol 2002;110(6):834-40
   PubMed Web of Science ®Google Scholar
• Nwaru BI, Hickstein L, Panesar SS, et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy 2014;69(8):992-1007
   PubMed Web of Science ®Google Scholar
• Onions D, Egan W, Jarrett R, et al. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals 2010;38(5):544-51
   PubMed Web of Science ®Google Scholar
• Medema JK, Wijnands DT, Palache AM. The role of MDCK-based influenza vaccine Influvac® TC in (inter) pandemics. Int Congr Ser 2004;1263:822-5
   Google Scholar
• Dormitzer PR. Cell culture-derived influenza vaccines. In: Del Giudice G, Rappuoli R, editors. Influenza vaccines for the future, 2nd edition. Springer Basel AG, 2011
   Google Scholar
• Yasuda Y, Komatsu R, Matsushita K, et al. Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv Ther 2010;27(7):444-57
   PubMedGoogle Scholar
• Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361(25):2424-35
   PubMed Web of Science ®Google Scholar
• Reynales H, Astudillo P, de Vallière S, et al. A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. Vaccine 2012;30(45):6436-43
   PubMedGoogle Scholar
• Chan CY, Tambyah PA. Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine. Expert Rev Vaccines 2012;11(7):759-73
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Questions and answers on the review of Preflucel and associated names (influenza vaccine, purified antigen). Available from: www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Preflucel/WC500130157.pdf
   Google Scholar
• Yang LP. Recombinant trivalent influenza vaccine (flublok(®)): a review of its use in the prevention of seasonal influenza in adults. Drugs 2013;73(12):1357-66
   PubMed Web of Science ®Google Scholar
• Traynor K. First recombinant flu vaccine approved. Am J Health Syst Pharm 2013;70(5):382
   PubMed Web of Science ®Google Scholar
• Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009;8(6):679-88
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Flucelvax clinical review. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM332069.pdf
   Google Scholar
• Suphaphiphat P, Keiner B, Trusheim H, et al. Human RNA polymerase I-driven reverse genetics for influenza a virus in canine cells. J Virol 2010;84(7):3721-5
   PubMedGoogle Scholar
• Peck H, Dodin J, Baas C, et al. Evaluation of growth, genetic, and antigenic characteristics of pandemic H1N1 viruses isolated and passaged in qualified MDCK suspension cells (MDCK33016PF) and embryonated hen eggs. Influenza Other Respir Viruses 2011;5(Suppl 1):366-9
   Google Scholar
• Roth B, Mohr H, Enders M, et al. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses. Vaccine 2012;30(3):517-22
   PubMed Web of Science ®Google Scholar
• Polovic N, Wadén K, Binnmyr J, et al. Dog saliva - an important source of dog allergens. Allergy 2013;68(5):585-92
   PubMedGoogle Scholar
• Wanich N, Bencharitiwong R, Tsai T, Nowak-Wegrzyn A. In vitro assessment of the allergenicity of a novel influenza vaccine produced in dog kidney cells in individuals with dog allergy. Ann Allergy Asthma Immunol 2010;104(5):426-33
   PubMedGoogle Scholar
• Bencharitiwong R, Leonard S, Tsai T, Nowak-Węgrzyn A. In vitro assessment of the allergenicity of novel MF59-adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. Hum Vaccin Immunother 2012;8(7):863-5
   PubMed Web of Science ®Google Scholar
• Note for guidance on harmonisation of requirements for influenza vaccines. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf
   Google Scholar
• Food and Drug Administration (FDA). Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Available from: www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm
   Google Scholar
• Reisinger KS, Block SL, Izu A, et al. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009;200(6):849-57
   PubMed Web of Science ®Google Scholar
• Vesikari T, Block SL, Guerra F, et al. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012;31(5):494-500
   PubMed Web of Science ®Google Scholar
• Ambrozaitis A, Groth N, Bugarini R, et al. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 2009;27(43):6022-9
   PubMedGoogle Scholar
• Szymczakiewicz-Multanowska A, Groth N, Bugarini R, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009;200(6):841-8
   PubMed Web of Science ®Google Scholar
• Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, et al. Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons. Hum Vaccin Immunother 2012;8(5):645-52
   PubMed Web of Science ®Google Scholar
• Vinnemeier CD, Fischer-Herr J, Meyer S, et al. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study. Hum Vaccin Immunother 2014;10(2):441-8
   PubMed Web of Science ®Google Scholar
• Loebermann M, Voss U, Meyer S, et al. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination. PLoS One 2013;8(8):e70866
   PubMedGoogle Scholar
• Pérez-Rubio A, Bouza JM. [An experience of the use of cell culture-derived influenza vaccines in an influenza vaccination campaign]. Gac Sanit 2014;28(1):88-9
   PubMedGoogle Scholar
• Belsey MJ, de Lima B, Pavlou AK, Savopoulos JW. Influenza vaccines. Nat Rev Drug Discov 2006;5(3):183-4
   PubMed Web of Science ®Google Scholar
• Willyard C. Cell-based vaccines yield only modest advances for seasonal flu. Nat Med 2013;19(1):4
   PubMed Web of Science ®Google Scholar
• Flucelvax pregnancy registry: an observational study on the safety of Flucelvax exposure in pregnant women and their offspring. Available from: www.clinicaltrials.gov/ct2/show/NCT02258178
   Google Scholar
• Safety, tolerability, and immunogenicity of GC3106 (quadrivalent cell-culture based influenza vaccine). Available from: www.clinicaltrials.gov/ct2/show/NCT02249221
   Google Scholar
• Study of the safety and immunogenicity of an influenza vaccine administered to healthy adults. Available from: https://clinicaltrials.gov/ct2/show/NCT00264576
   Google Scholar
• Safety and immunogenicity of a cell culture-derived influenza vaccine in healthy adults and elderly. Available from: https://clinicaltrials.gov/ct2/show/NCT00492063
   Google Scholar
• Comparison of safety, tolerability and immunogenicity of influenza vaccines in adults and elderly. Available from: https://clinicaltrials.gov/ct2/show/NCT00306527
   Google Scholar
• Safety and immunogenicity of 3 lots of cell-derived subunit influenza vaccine as compared to 1 lot to egg-derived subunit influenza vaccine in healthy adults (≥18 to ≤60). Available from: https://clinicaltrials.gov/ct2/show/NCT00310804
   Google Scholar
• Second extension study to evaluate safety and tolerability of influenza vaccines in adults and elderly, and to evaluate immunogenicity and concomitant vaccination with pneumococcal vaccine in a subgroup. Available from: https://clinicaltrials.gov/ct2/show/NCT00579345
   Google Scholar
• Pediatric safety and immunogenicity study of cell-culture derived and egg-based subunit influenza vaccines in healthy children and adolescents. Available from: https://clinicaltrials.gov/ct2/show/NCT00645411
   Google Scholar
• Efficacy study of two influenza vaccines and placebo in healthy adult subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT00630331
   Google Scholar
• Safety and immunogenicity of one dose of a surface, antigen, inactivated, influenza vaccine produced in mammalian cell culture administered to adult and elderly subjects. Available from: https://clinicaltrials.gov/ct2/show/NCT01422512
   Google Scholar
• Safety and immunogenicity of a cell derived subunit trivalent nonadjuvated influenza study vaccine in adults aged 18 years and above. Available from: https://clinicaltrials.gov/ct2/show/NCT01640314
   Google Scholar